STAT July 30, 2024
Elaine Chen

Good morning. If anything will motivate me to get through this week, it’s knowing that Simone Biles went on to nail the most difficult vault even while experiencing calf problems. That and also everyone’s new obsession over pommel horse king Stephen Nedoroscik.

As much as I would want to continue talking about the Olympics, though, we still have biotech news to get to.

The need-to-know this morning

  • Pfizer earnings are here, Merck earnings are here. Keytruda sales were $7.3 billion, or 45% of Merck’s total revenue for the second quarter.
  • BioNTech and Regeneron Pharmaceuticals reported results from a mid-stage study of their mRNA-based immunotherapy for melanoma.
  • Day One Pharmaceuticals reported $8.2 million in second-quarter sales for Ojemda, a treatment...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Insurance, Medicare, Pharma / Biotech
Related Articles:
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
GLP-1 drug coverage for obesity making inroads with large employers: Mercer

Share This Article